FMS

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.

Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.

FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.

Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.